Navigation Links
Schering-Plough Announces Results of the Early ACS Trial
Date:3/30/2009

p>

No statistical difference was observed between the groups in either the primary or secondary endpoints. The primary endpoint occurred in 9.3 percent of the study group (receiving double-bolus plus infusion early administration of eptifibatide 12 or more hours prior to angiography), compared with 10.0 percent of the delayed provisional group (p=0.23). At 30 days, the death or (re)MI rate for the study group was 11.2 percent compared to 12.3 percent for the delayed provisional group (p=0.079).

Significantly higher rates of bleeding were observed in the study group, with 118 patients experiencing a TIMI major bleeding event, compared to 83 in the delayed provisional group (p=0.015). Investigators reported a 7.6 percent vs. 5.1 percent rate of moderate or severe bleeding (p<0.001) in the study group as compared to the delayed provisional group, as measured by the GUSTO scale. Red blood cell transfusions occurred in 8.6 percent of patients in the study group vs. 6.7 percent of patients in the delayed provisional group (p=0.001). There were no significant differences in mortality or any serious adverse events between the two groups.

"This was a very well-treated population that demonstrates the influence of aggressive and sophisticated therapies," said Dr. Newby. "Further evaluation of the safety and efficacy data at one year should provide additional insights into the early use of eptifibatide in this patient population."

Within the trial, the single largest group was PCI patients (n=5,559). An analysis of those randomized to receive early eptifibatide showed that these patients experienced fewer primary and secondary composite events after PCI than those randomized to the delayed provisional eptifibatide strategy.

"Consistent with findings from prior trials, in this double-bolus study, NSTE ACS patients undergoing PCI experienced fewer post-PCI ischemic complications with early eptifibat
'/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
2. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
3. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
4. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
5. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
6. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... ANAHEIM, Calif. , July 28 Siemens ... services and solutions for clinicians at the American Association for ... from July 27 through July 29, 2010 ... demonstrating how Siemens is focused on putting the power behind ...
... Commitment to Patient Safety; Approved Sites Eligible to Advertise through Search ... , , ... 28 The National Association of Boards of Pharmacy ® ... Drug as the first online pharmacy services to be approved through ...
Cached Medicine Technology:Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 2Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 3Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 4Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 5Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 6NABP Grants First 'Approved e-Advertiser' Status to Pharmahelper.com, QC Supply, and Kerr Drug 2NABP Grants First 'Approved e-Advertiser' Status to Pharmahelper.com, QC Supply, and Kerr Drug 3
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... which patients might suffer potentially fatal side-effects from a ... brain scans using pattern recognition software similar to that ... developed by researchers at Imperial College London. Results of ... used the software are published in the journal ... million people each year worldwide. Ischemic strokes are the ...
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... a movie may induce enough stress to interfere with ... time you sit down to watch a violent or ... problem-solving ability. ,David Beversdorf, a neurologist at the ... women and asked them to combine movie viewing with ...
... develop complications with the placenta during pregnancy appear to ... // . ,The study, published in the ... risk of premature cardiovascular disease doubled when she had ... gestational high blood pressure and separation of the placenta ...
... considered as an important breakthrough in our still limited ... new gene linked to major mental illness // ... to increase the risk of schizophrenia and depression. ... together with scientists from the pharmaceutical company Merck, Sharp ...
... professional colleges regarding the issue of having a common ... // . Few educational institutions are under the opinion ... marks alone. ,Following the judgment of the Supreme ... upon admission on their own, an entity called All ...
... anthrax outbreak in Makassar, Indonesia, has infected at least five ... Post // . ,The human infections came to light ... in Tamangapa subdistrict have died of anthrax recently. ... the five persons after it was discovered that the cattle ...
... chill was just starting to set in when the world's ... down a ramp under a starry sky at a show ... awareness.// ,Glebova was also joined by Miss ... the show here Wednesday night to promote awareness about AIDS., ...
Cached Medicine News:Health News:A Step Towards Unraveling The Schizophrenia And Depression Mystery 2Health News:Mixed Opinion Regarding Common Medical And Engineering Entrance Test 2Health News:Five People Treated For Anthrax In Indonesia 2Health News:Miss Universe Walks The Ramp For AIDS Awareness 2
... microplate incubator is an extremely compact ... single microplate up to 50C. ... requiring higher temperatures up to 65C. ... low cost and high performance for ...
... The Solo microplate incubator is an ... incubating a single microplate up to ... incubates applications requiring higher temperatures up ... solution offering low cost and high ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: